Circulating tumor cells and biomarker modulation with olaratumab monotherapy followed by olaratumab plus doxorubicin: Phase ib study in patients with soft-tissue sarcoma

Javier Martín-Broto, A. L. Pousa, Andrew S. Brohl, Brian A. van Tine, Benjamin Powers, Silvia Stacchiotti, Jean Yves Blay, James S. Hu, Gerard J. Oakley, Hong Wang, Anna M. Szpurka, Donna E. Levy, Gary Mo, Matteo Ceccarelli, Robin L. Jones

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

This phase Ib study enumerated whole blood circulating tumor cells (CTC) and evaluated biomarkers in patients with potentially resectable soft-tissue sarcoma (STS) treated with olaratumab monotherapy (20 mg/kg) for one cycle followed by up to six cycles of olaratumab (20 mg/kg, cycles 1–2; 15 mg/kg, cycles 3–7) plus doxorubicin (75 mg/m2 on day 1). CTCs, platelet-derived growth factor receptors (PDGFR), and PDGF ligand expression in tumor tissue pre- and post-olaratumab monotherapy were evaluated. Antitumor activity, safety, pharmacokinetics, and PET/biomarker association with clinical outcome were assessed. Of 51 treated patients, 35, 43, and 37 were evaluable for CTC enumeration, PDGFRs, and PDGF ligand expression, respectively. An increase in CTCs at cycle 1 day 8 was observed, followed by a significant reduction by cycle 3 day 1 or 30-day follow-up. Decrease in CTC counts after olaratumab monotherapy was higher in patients with disease control than without disease control (57.9% vs. 31.2%). Baseline IHC expression was positive in most patients for PDGFRa [n ¼ 31 (72.1%)] and PDGFRb [n ¼ 36 (83.7%)]. Similar rates were observed post-olaratumab monotherapy [PDGFRa, n ¼ 30 (69.8%); PDGFRb, n ¼ 33 (76.7%)]. Eleven patients (29.7%) showed a 30% reduction by RT-PCR in PDGFRa at cycle 2. PDGFR expression and PET response showed no correlation with clinical outcome. Safety and pharmacokinetic profiles were consistent with previous reports. This study, the first to use a validated method for CTC detection, confirms that CTC enumeration in STS is feasible. However, no correlation was observed between PDGFRa expression and clinical outcome.

Original languageEnglish
Pages (from-to)132-141
Number of pages10
JournalMolecular Cancer Therapeutics
Volume20
Issue number1
DOIs
StatePublished - Jan 1 2021

Fingerprint

Dive into the research topics of 'Circulating tumor cells and biomarker modulation with olaratumab monotherapy followed by olaratumab plus doxorubicin: Phase ib study in patients with soft-tissue sarcoma'. Together they form a unique fingerprint.

Cite this